Fundamental Analysis of ALLOGENE THERAPEUTICS INC(NASDAQ:ALLO) stock

Fundamental Rating

ALLO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. ALLO has a great financial health rating, but its profitability evaluates not so good. ALLO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALLO had negative earnings in the past year.

In the past year ALLO has reported a negative cash flow from operations.

In the past 5 years ALLO always reported negative net income.

In the past 5 years ALLO always reported negative operating cash flow.

1.2 Ratios

ALLO has a worse Return On Assets (-87.93%) than 74.36% of its industry peers.

ALLO has a Return On Equity of -110.36%. This is comparable to the rest of the industry: ALLO outperforms 42.91% of its industry peers.

		Industry Rank	Sector Rank
ROA	-87.93%
ROE	-110.36%
ROIC	N/A

ROA(3y)-38.79%

ROA(5y)-32.49%

ROE(3y)-47.3%

ROE(5y)-38.88%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALLO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALLO does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALLO has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, ALLO has more shares outstanding

ALLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ALLO has an Altman-Z score of -2.79. This is a bad value and indicates that ALLO is not financially healthy and even has some risk of bankruptcy.

ALLO has a Altman-Z score of -2.79. This is comparable to the rest of the industry: ALLO outperforms 45.98% of its industry peers.

ALLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-2.79

ROIC/WACCN/A

WACC9.23%

2.3 Liquidity

ALLO has a Current Ratio of 12.38. This indicates that ALLO is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of ALLO (12.38) is better than 85.47% of its industry peers.

ALLO has a Quick Ratio of 12.38. This indicates that ALLO is financially healthy and has no problem in meeting its short term obligations.

ALLO has a better Quick ratio (12.38) than 85.47% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	12.38
Quick Ratio	12.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.36% over the past year.

Looking at the last year, ALLO shows a very negative growth in Revenue. The Revenue has decreased by -10.00% in the last year.

EPS 1Y (TTM)13.36%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q34.85%

Revenue 1Y (TTM)-10%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q90%

3.2 Future

Based on estimates for the next years, ALLO will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.02% on average per year.

ALLO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 457.13% yearly.

EPS Next Y15.76%

EPS Next 2Y10.46%

EPS Next 3Y4.61%

EPS Next 5Y17.02%

Revenue Next Year-68.46%

Revenue Next 2Y628.95%

Revenue Next 3Y625.17%

Revenue Next 5Y457.13%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALLO. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALLO. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y10.46%

EPS Next 3Y4.61%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALLO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ALLOGENE THERAPEUTICS INC

NASDAQ:ALLO (4/19/2024, 1:32:34 PM)

3.425

-0.04 (-1.01%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap579.13M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-87.93%
ROE	-110.36%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	12.38
Quick Ratio	12.38
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)13.36%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y15.76%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-10%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ALLOGENE THERAPEUTICS INC (ALLO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens